A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC 704865 IND 7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer.

Next Previous
Trial Profile

A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC 704865 IND 7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 01 Feb 2012 Health-related quality-of-life substudy results published in the Journal of Pain and Symptom Management.
    • 02 Mar 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 06 Jul 2010 Results published in Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top